Truist Financial Reaffirms ‘Buy’ Rating for Jazz Pharmaceuticals Stock

🌥️Trending News

Truist Financial has reaffirmed their ‘Buy’ rating for Jazz Pharmaceuticals ($NASDAQ:JAZZ) stock. Truist analysts have praised the company’s recent performance and potential growth prospects. Jazz Pharmaceuticals is a biopharmaceutical company that develops and commercializes products to treat unmet medical needs in specialty markets worldwide. The company focuses on sleep and hematology/oncology areas, and its products include Xyrem, Defitelio, Erwinaze, and Vyxeos. Its marketed products are used to treat narcolepsy, hematologic malignancies, and other diseases.

In addition, Jazz Pharmaceuticals has several product candidates in various stages of development. The Truist analysts have given a “Buy” recommendation to Jazz Pharmaceuticals stock, citing the company’s strong financial performance, robust product portfolio, and promising growth prospects. They believe that the company is well-positioned for the future and has a strong track record of delivering shareholder value.

Market Price

The stock opened at $120.8 and closed at $119.6, marking a 1.7% decrease from its prior closing price of $121.6. Despite the short-term market fluctuations, investors remain confident in the company’s future prospects and believe its long-term outlook remains strong. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Jazz Pharmaceuticals. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Jazz Pharmaceuticals. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Jazz Pharmaceuticals. More…

Key Ratios Snapshot

Some of the financial key ratios for Jazz Pharmaceuticals are shown below. More…

Analysis

At GoodWhale, we take a deep dive into the fundamentals of JAZZ PHARMACEUTICALS to determine its financial health. Our Star Chart analysis reveals that the company has a high health score of 7/10 when it comes to cashflows and debt, indicating that it is capable to safely ride out any crisis without the risk of bankruptcy. When looking at JAZZ PHARMACEUTICALS’s performance with regard to other metrics, we see that it is strong in asset, growth, and profitability but weak in dividend. We classify the company as a ‘rhino’, meaning that it has achieved moderate revenue or earnings growth. These findings make JAZZ PHARMACEUTICALS an attractive investment for investors who are looking for long term returns. The company is well-positioned to weather any crisis and has demonstrated consistent performance in terms of asset growth and profitability. As a result, investors looking for a reliable stock with the potential for long term gains may find JAZZ PHARMACEUTICALS an appealing option. More…

Peers

The company has a diversified portfolio of products in central nervous system, hematology/oncology, inflammation and other therapeutic areas. Jazz Pharmaceuticals‘ competitors include Nurix Therapeutics Inc, Incyte Corp, and Poxel SA.

– Nurix Therapeutics Inc ($NASDAQ:NRIX)

Nurix Therapeutics Inc. is a clinical-stage biopharmaceutical company, which focuses on harnessing the body’s own natural mechanisms to regulate protein function for the treatment of cancer and other diseases. The company’s lead product candidate is a first-in-class, orally available, small molecule inhibitor of the proteasome, which is in development for the treatment of relapsed or refractory multiple myeloma. Nurix was founded by Robert L. Gould, Ph.D. and Bruce A. Cohen, M.D. in December 2001 and is headquartered in San Francisco, CA.

– Incyte Corp ($NASDAQ:INCY)

Incyte Corp is a biopharmaceutical company that focuses on the discovery, development, and commercialization of proprietary therapeutics to treat serious unmet medical needs, primarily in oncology. The company’s market cap is 15.34B as of 2022 and its ROE is 9.54%. Incyte’s products include Jakafi, Iclusig, and Jakavi. Jakafi is used to treat myelofibrosis and polycythemia vera, two rare blood disorders. Iclusig is used to treat leukemias, including chronic myeloid leukemia andPhiladelphia chromosome-positive acute lymphoblastic leukemia. Jakavi is used to treat myelofibrosis, polycythemia vera, and essential thrombocythemia.

– Poxel SA ($LTS:0RA2)

Poxel SA is a French pharmaceutical company that focuses on the development and commercialization of drugs for the treatment of diabetes and obesity. The company has a market capitalization of 43.37 million as of 2022 and a return on equity of -705.2%. Poxel SA’s products include Imeglimin, which is in clinical development for the treatment of type 2 diabetes, and PXL065, which is in preclinical development for the treatment of obesity.

Summary

Truist Financial recently reaffirmed its stock rating of “Buy” for Jazz Pharmaceuticals. This reiterates the optimism among investors for Jazz Pharmaceuticals, a biopharmaceutical company that develops and commercializes products for various therapeutic areas, including neurology, pediatric, and orphan diseases. Analysts believe Jazz Pharmaceuticals will continue to benefit from strong fundamentals, a diverse product portfolio, and an expanding pipeline of promising drugs. Furthermore, the company’s strong balance sheet and cash position provide it with operational flexibility and capital to invest in long-term sustainability and growth.

Additionally, Jazz Pharmaceuticals’ strategic partnerships with large pharmaceutical corporations, such as Pfizer and Sanofi, are expected to drive future growth. All in all, analysts remain positive on the stock’s long-term prospects.